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INTRODuCTION
the controlled silencing of target genes is important both for 
molecular biological studies and for related applied sciences: 
in particular, modern biomedicine.
Among the many gene silencing approaches (which include 
the use of anti-sense rnA, ribozymes, chemical blockers, and 
targeted mutagenesis), the most efficient approach is based 
on rnA-interference.
rnA interference is a highly specific mechanism for the 
posttranscriptional silencing of target genes. It involves the 
degradation of the target gene mrnA. the degradation of 
mrnA occurs in a complex formed by short-interfering rnA 
oligonucleotides (sirnA) and cellular proteins such as endo-
nucleases. the nucleotide sequence of sirnA is complemen-
tary to that of target gene mrnA.
In the past couple of years, the use of sirnA has become 
widespread in studies of gene functioning and gene interac-
tion. the use of sirnA as next generation therapeutic agents 
in biomedicine is also being explored. It is possible that, in the 
near future, sirnA will be used for treating viral and onco-
logical diseases.
currently, short synthetic 21–22-bp double-stranded sir-
nA molecules are widely used to silence mammalian genes. 
A number of commercial firms synthesize sirnA oligonu-
cleotides. these commercial firms have sirnA design tools 
available on their websites (e.g., www.qiagen.com). Synthetic 
sirnA oligonucleotides are transferred into cells in vitro by 
lipofection. Since sirnA induces the degradation of mrnA 
(and not the protein directly), the silencing effect does not 
occur immediately after cell transfection. the silencing ef-
fect is generally noticeable within 18 hours of transfection: 
however, in the case of stable proteins, the silencing effect 
may be noticeable only 24–48 hours after transfection. the 
longevity of sirnA silencing is comparatively short, and dif-
ferent sources claim that the silencing effect lasts for 3–5 cell 
divisions. It should be noted that the longevity of sirnA si-
lencing may depend on many factors, in particular the nature 
of the cells being transfected. Approaches have been devel-
oped to synthetically modify sirnA oligonucleotides, which 
enhance the longevity of sirnA silencing in cells. Such syn-
thetically modified sirnA oligonucleotides are useful for the 
post-transcriptional silencing of genes that encode proteins 
with a long half-life.
For long-lasting gene silencing, shrnA expressing lenti- 
and retroviral vectors can be used. nucleotide sequences en-
coding the sense and antisense strands of sirnA separated by 
a spacer sequence can be cloned into lenti- or retroviral vector 
constructs using standard molecular biological cloning tech-
niques. the transcription of such nucleotide sequences leads 
to the formation of shrnA molecules. shrnA molecules form 
a hairpin structure consisting of two complimentary strands 
separated by a loop (spacer). the cellular endonuclease dicer 
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is responsible for the cleavage of shrnA molecules. As a re-
sult, the loop (spacer) gets removed from shrnA molecules 
and double-stranded sirnA molecules are formed. these 
sirnA molecules are capable of initiating the degradation of 
target gene mrnA.
Within the framework of our project, we were able to 
silence the expression of activated oncogenes AML1-etO 
(t8;21) and runX1(K83n) with the help of rnA interfer-
ence. these activated oncogenes are frequently found in 
acute myeloid leukemia patients. We were able to compare 
the efficiency of gene silencing (a) after the lipofection of 
oncogene-expressing model cell lines with synthetically 
modified double-stranded sirnA oligonucleotides and (b) 
after the transduction of oncogene-expressing model cell 
lines with shrnA-expressing recombinant lentiviral vector 
particles.
Oncogene-expressing model cell lines were obtained from 
murine Sc1 embryonic fibroblast cell lines after their trans-
duction with bicistronic retroviral vector particles. these 
retroviral vectors contained a bicistronic expression cassette 
comprised of the gene of interest and an eGFP marker gene 
separated by an IreS sequence and driven by a common 
promoter. the following genes were selected as genes of in-
terest:
(1) the AML1-etO fusion gene, which is formed as a re-
sult of the t(8:21) chromosomal translocation.
(2) the activated runX1-K83n oncogene, which is 
formed as a result of a point mutation in the runX1 gene 
and leads to the substitution of lysine to asparagine in the 83 
position of the runX1 protein. Since both the gene of inter-
est and eGFP marker gene are driven by a common promot-
er, the expression levels of the gene of interest in cells can be 
evaluated based on the intracellular expression of the eGFP 
marker gene.
the typical results of transduction efficiency and trans-
gene expression are shown in Fig. 1. 
throughout the course of our work, we used the murine 
Sc1 embryonic fibroblast cell line, the HeK 293 cell line, 
and two transgenic Sc1 cell lines expressing either activated 
oncogene AML1-etO or runX1(K83n). All four cell lines 
were cultured in standard DMeM medium containing 10% 
FBS, 4mM L-glutamine, 1mM sodium pyruvate, 100 mkg/
ml streptomycin, and 100 units/ml penicillin at 37 ˚С in a 5% 
СО2 atmosphere.
the design and synthesis of double-stranded sirnA mol-
ecules was carried out in collaboration with the Institute of 
chemical Biology and Fundamental Medicine, Siberian Branch 
of the russian Academy of Sciences (IcBFM SB rAS). the 
oligonucleotides were synthesized at IcBFM SB rAS using 
the phosphamide method. During oligonucleotide synthesis, a 
unique method was used to methylate the oligonucleotides at 
certain positions. these modifications significantly increase the 
lifespan of synthetic sirnA in cells. the nucleotide sequences 
of sirnA oligonucleotides and the oncogene mrnA zones be-
ing targeted by them are shown in table. 1. 
Anti-AML1-etO and anti-runX1 sirnA duplexes were 
transferred into transgenic Sc1 cell lines by lipofection us-
ing Lipofectamin2000 (Invitrogen) as per the manufacturers’ 
protocol. the final concentration of sirnA duplexes in the 
transfection culture medium was 200nM. Four hours after 
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Fig. 1. Efficiency of transgene expression in cell lines transduced with 
AML1-ETO- and RUNX1-K83N-expressing recombinant retroviral vector 
particles; (A) Histogram of nontransduced SC-1 murine fibroblast cell 
line, (B) 
Histogram of SC-1 murine fibroblast cell line transduced with RUNX1-
K83N expressing retroviral vector particles (74,22 % of the population 
shows increased fluorescence), (C) Histogram of SC-1 murine fibroblast 
cell line transduced with AML1-ETO expressing retroviral vector parti-
cles (72,64 % of the population shows increased fluorescence). The ab-
solute values of the size of each event analyzed (cell) is shown along the 
X axis, while the absolute values of the intensity of fluorescence of each 
event (cell) is shown along the Y axis. Every third histogram in each row 
is divided into 4 quadrants; the upper right quadrant contains cells ex-
pressing eGFP and AML1-ETO, while the lower right quadrant contains 
cells that do not express eGFP and AML1-ETO. (D) RT-PCR (from left to 
right; (a) non transduced SC-1 cell line, (b) SC-1 cell line transduced with 
RUNX1-K83N expressing retroviral vector particles, (c) SC-1 cell line 
transduced with AML1-ETO expressing retroviral vector particles)88 | ActA nAturAe |  № 2 2009
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transfection, the culture medium was changed to a fresh me-
dium. the transfected cell lines were cultured at 37 ˚С in a 5% 
СО2 atmosphere for 72 hours.
the level of oncogene expression in the cell lines was eval-
uated by reverse transcription Pcr (rt-Pcr) and flow cy-
tometry. the total mrnA from the cell lines was extracted 
using trizol (Invitrogen) as per the manufacturers’ protocol. 
the extracted mrnA was used to synthesize the first strands 
of cDnA using the ImProm-II™ reverse transcriptase 
(Promega) kit.
Pcr with sequence-specific primers was carried out to 
identify the nucleotide sequences of the genes of interest and 
eGFP marker gene in the total cDnA. the following primers 
were used for runX1(K83n): sense-AGtcctAccAAtAc-
ctGGGA; antisense-tctcAGctGtGGtGGtGAAG, for 
AML1/etO: sense-cAtttcAcccGAGAtAGGAG; anti-
sense-AAGtcctcGGcGtcActGAt, for eGFP : sense-Ac-
ctAcGGcctGcAGtGctt; antisense-tGccGttcttct-
GcttGtcG. Pcr products were then visualized after 1.5% 
agarose gel electrophoresis. the results were processed using 
the Gel-Pro Analyzer 4.0 software, which gives a maximum 
optical density (maxOD) reading. the results were normal-
ized against β-actin.
cell fluorescence was measured using an epics 4XL Beck-
man coulter flow cytometer (united States). the WinMDI2.8 
software program was used for data collection and data 
analysis. the diagrams of the percentage of fluorescent cells 
in the cell populations are shown in Fig. 2. cell populations 
transfected with respective sirnA duplexes are shown along 
the X axis, while the percentage of fluorescent cells in the 
population is shown on the Y axis.
results obtained by flow cytometry correlate well with 
the results obtained by rt-Pcr. the electrophoregram of 
rt-Pcr products is shown in Fig. 4. the reduction of onco-
gene mrnA is clearly visible in the Sc1-AML1/etO(t8;21) 
transgenic cell lines transfected with sirnA oligonucleotides 
targeting the 5’-end of runX1 mrnA, etO mrnA and the 
site of junction of AML1-etO mrnA. Oncogene mrnA re-
duction is also seen in the Sc1-runX1(K83n) transgenic cell 
lines transfected with sirnA oligonucleotides targeting the 
5’- and 3’-ends of runX1 mrnA.
While there is a significant reduction of fluorescence in 
a portion of the cell population (two times or more) after 
the addition of synthetic sirnA, there is no such reduc-
tion in fluorescence in the rest of the cell population (Fig. 
3). this coincides with the results obtained by rt-Pcr (Fig. 
3). the most likely reason for this is the low efficiency of 
sirnA delivery into cells. According to the manufacturers 
of Lipofectamin2000 (Invitrogen), the lipofection efficiency 
with sirnA oligonucleotides is 50–60% and depends on the 
nature of the cells being transfected. Apart from this, there 
is the possibility of a reduction of synthetic sirnA activ-
ity due to their enzymatic degradation, which is catalyzed 
by cellular endonucleases, despite the stabilizing modifica-
tions introduced to the sirnA oligonucleotides. According to 
our data, the maximum interfering activity of synthetically 
modified sirnA is observed 48–72 hours post transfection.
the gene silencing kinetics of synthetic sirnA oligonucle-
otides targeting the junction point of AML1-etO mrnA is 
illustrated in Fig. 4. the moment of sirnA transfection has 
been taken as zero-time reference.
It has been shown that the maximum silencing activity of 
synthetic sirnA is 48–72 hours post transfection, when the 
percentage of fluorescent cells in the population is around 
56%. the percentage of fluorescent cells in the population 
increases to 67.92 and 74.39% 96 and 120 hours post trans-
fection, respectively. the results shown are averaged from 
three parallel measurements and are in reference to a con-
trol.
the efficiency of rnA-interference can be increased by 
increasing the efficiency of sirnA delivery into the model 
cell lines. For this purpose, taking into account the efficiency 
of the synthetic sirnA duplexes, two shrnA-expressing 
lentiviral vectors were constructed targeting the junc-
tion point of AML1-etO mrnA and the 5`-end of runX1 
mrnA, respectively. the lentivectors were constructed 
by cloning the shrnA-expressing DnA sequence into the 
pLSLP vector.
DnA sequence which encodes anti AML1-etO shrnA
AML1-etO-sense
5’-p-gatccgcctcGAAAtcGtActGAGGcttcctgt-
catctcAGtAcGAtttcGAGGtttttg-3’
AML1-etO antisense
5’-p-aattcaaaaacctcGAAAtcGtActGAGAtgacag-
gaagcctcAGtAcGAtttcGAGGcg-3’
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Fig. 2. Results obtained after flow cytometric analysis of cell suspensions. 
The percentage of fluorescent cells in the population of different siRNA 
transfected cell lines is shown. A) The percentage of fluorescent cells in 
the AML1-ETO expressing murine fibroblast cell line 48 hours after trans-
fection with various siRNA duplexes.  B) The percentage of fluorescent 
cells in the RUNX1(K83N) expressing murine fibroblast cell line 48 hours 
after transfection with various siRNA duplexes
Fig. 3. The electrophoregram of RT-PCR products of total cDNA 
obtained from oncogene expressing model cell lines transfected with 
siRNA. 1) siRNA(AML1-5`), 2. siRNA(AML1-3`), 3. siRNA(AML1-ETO), 
4. siRNA(ETO), 5. Control (without siRNA)reSeArcH ArtIcLeS
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DnA sequence which encodes anti-runX1 shrnA
AML-5-sense
5’-p-gatccgGAAccAGGttGcAAGAttccttcctgt-
caAAAtcttGcAAcctGGttctttttg-3’
AML-5-antisense
5’-p-aattcaaaaaGAAccAGGttGcAAGAttttgacag-
gaagGAAtcttGcAAcctGGttccg-3’
the design of the shrnA-coding DnA sequences was done 
through an internet resource (http://gesteland.genetics.utah.
edu/sirnA_scales/index.html). Standard genetic engineer-
ing techniques were used for all cloning procedures. the vec-
tor maps of the constructed shrnA-expressing lentiviral vec-
tors are shown in Fig. 5.
the transient cotransfection of HeK293 t cells with 
shrnA-expressing lentiviral vectors and packaging plas-
mids was done for the production of shrnA-expressing 
lentiviral vector particles. the transfection was carried 
out using Lipofectamin2000 (Invitrogen) as per the manu-
facturers’ protocol. Viral stocks were harvested for three 
days and used for the infection/transduction of the trans-
genic model cell lines expressing the activated oncogenes 
AML1-etO and runX1(K83n). Forty-eight hours after 
transduction/infection, the model cell lines were placed in 
culture media containing puromycin (10mkg/ml) for five 
days. After selection for puromycin resistance, the shrnA-
expressing transduced model cell lines were analyzed by 
flow cytometry.
the percentage of fluorescent cells in the Sc1-AML1/
etO(t8;21) transgenic cell line decreased 6 times after their 
transduction with shrnA-expressing lentiviral vector par-
ticles targeting the junction point of AML1-etO mrnA 
(Fig. 6). Similar results were seen when the Sc1-AML1/
etO(t8;21) and Sc1-runX1(K83n) cell lines were trans-
duced with shrnA-expressing lentiviral vector particles 
targeting the 5`-end of runX1 mrnA. the percentage of 
fluorescent cells in the cell lines decreased 8 and 8.5 times, 
respectively. It should be noted that the Sc1-runX1(K83n) 
cell line showed no reduction in fluorescence when trans-
Hours
100 %
77.98 %
56.25 % 56.50 %
67.92 % 74.39 %
0  24  48  72  96  120  144
100
80
60
40
20
 
P
e
r
c
e
n
t
a
g
e
 
o
f
 
t
h
e
 
f
l
u
o
r
e
s
c
e
n
t
-
b
r
i
g
h
t
 
c
e
l
l
s
 
i
n
 
r
a
t
i
o
 
t
o
 
t
h
e
 
c
o
n
t
r
o
l
 
o
n
e
. А.
АmpR
pLSLP-AML-ETO-shRNA
6986 bp
RSV LTR
HIV LTR
env
cPPT
H4-promoter
puro
WPRE
AML-ETO shRNA
H1 RNA
3' dLTR
SV40 ELL poly(A)s
SV40 Ori
Ori
Nde I (6767)
Mlu I (2)
Bgl II (254)
Hin dIII (312)
Hin dIII (865)
Hin dIII (1448)
Cla I (1918)
Nco I (3193)
gag
Not I (922)
Xba I (2170)
Sal I (2779)
Kpn I (3397)
Eco RI (3496)
Bam HI (3556)
Sfi I (4281)
Bgl II (3429)
Cla I (3778)
Bgl II (3821)
Hin dII (3879)
Nco I (4235)
АmpR
pLSLP-AML-shRNA
6986 bp
RSV LTR
HIV LTR
env
cPPT
H4-promoter
puro
WPRE
H1 RNA
3' dLTR
SV40 ELL poly(A)s
SV40 Ori
Ori
Bgl II (254)
Hin dIII (312)
Hin dIII (865)
Hin dIII (1448)
Cla I (1918)
Nco I (3193)
gag
Mlu I (2)
B.
Bgl II (3429)
Cla I (3778)
Bgl II (3821)
Hin dII (3879)
Nco I (4235)
Not I (992)
Xba I (2170)
Sal I (2779)
Kpn I (3397)
Eco rI (3496)
Bam HI (3556)
Sfi I (4281)
Nde I (6767)
AML shRNA
Fig. 4. The gene silencing kinetics of synthetic siRNA oligonucleotides 
targeting the junction point of AML1-ETO mRNA
Fig 5. shRNA expressing lentiviral vectors; (A) pLSLP-AML-ETO-shRNA: 
lentiviral vector expressing shRNA targeting the junction point of AML1-
ETO mRNA, (B) pLSLP-AML-shRNA: lentiviral vector expressing shRNA 
targeting the 5`-end of RUNX1-K83N mRNA90 | ActA nAturAe |  № 2 2009
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duced with shrnA-expressing lentiviral vector particles 
targeting the junction point of AML1-etO mrnA. the re-
sults obtained by flow cytometry correlate well with the re-
sults obtained by rt-Pcr (the electrophoregram is shown 
in Fig. 7).
CONCLuSIONS
Our results illustrate the high efficiency of stable syntheti-
cally modified sirnA duplexes for silencing the activated 
oncogenes frequently found in acute myeloid leukemia pa-
tients.
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Fig 6. Histogram illustrating the reduction in fluorescence in the AML1-
ETO expressing SC-1 murine fibroblast cell line: (A) before transduction, 
(B) after transduction with shRNA-expressing lentiviral vector particles 
targeting the junction point of the AML1-ETO mRNA
Fig. 7. The electrophoregram of RT-PCR products of total cDNA ob-
tained from RUNX1(K83N) and AML1-ETO oncogene expressing SC1 
model cell lines transduced with shRNA expressing lentiviral vector 
particles: 99K - control  (non-transduced RUNX1(K83N) expressing SC1 
cell line); shA-E - RUNX1(K83N) expressing SC1 cell line transduced with 
shRNA expressing lentiviral vector particles targeting the junction point 
of AML1-ETO mRNA; shA5`  - RUNX1(K83N) expressing SC1 cell line 
transduced with shRNA expressing lentiviral vector particles targeting 
the  5`-end of RUNX1 mRNA . sc1K - control (non transduced SC1 cell 
line); last three samples - Analysis of AML1-ETO(t8;21) expressing SC1 
cell lines (98k - non transduced control, shA-E, sh5` - transduced with 
corresponding lentiviral vector particles)
Table
target chain sequence
AML-etO
sense 5’-ccucGAAAucGumAcumGAGUAG-3’
antisense 5’-ucucmAGumAcGAuuucGAGGuu-3’
etO
sense 5’-GGccmAGcGGumAcmAGuccmAGAu-3’
antisense 5’-uumGGAcumGumAccGcumGGccuG-3’
AML (5’)
sense 5’-GAAccmAGGuumGcmAAGAuuGAA-3’
antisense 5’-AAAucuumGcmAAccumGGuucuu-3’
AML (3’)
sense 5’-AGcccGGGAGcuumGuccuCuu-3’
antisense 5’-AAGGAcmAAGcucccGGGcuumG-3’
siPhk
1. AML5' 
2. AML3'
3. AML1-ETO
4. ETO
RUNX1
AML1-ETO
AML5fusion  ETO3'
AMLS'  AML3'
1  2
1  3  4
Validated sirnA sequences were used to design and syn-
thesize shrnA-coding DnA sequences. the synthesized DnA 
sequences were cloned into a recombinant lentiviral vector. 
the shrnA-expressing lentiviral vector particles target-
ing the junction point of AML1-etO mrnA and 5`-end of 
runX1 mrnA were used to transduce the oncogene-ex-
pressing model cell lines. the transduced model cell lines 
were analyzed by rt-Pcr and flow cytometry. the analysis 
revealed a significant reduction in the expression of activated 
oncogenes in the transduced cell lines. this is indicative of the 
high efficiency of the constructed lentiviral vector constructs, 
which can be used for silencing target genes by rnA inter-
ference.   
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